Nuria Quintana

1.1k total citations
7 papers, 646 citations indexed

About

Nuria Quintana is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Nuria Quintana has authored 7 papers receiving a total of 646 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 5 papers in Hematology. Recurrent topics in Nuria Quintana's work include Multiple Myeloma Research and Treatments (5 papers), Protein Degradation and Inhibitors (4 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Nuria Quintana is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Protein Degradation and Inhibitors (4 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Nuria Quintana collaborates with scholars based in Spain. Nuria Quintana's co-authors include Jesús F. San Miguel, Felipe de Arriba, Luis Palomera, María‐Victoria Mateos, Joan Bladé, Juan Luis Garcı́a, Felipe Prósper, Miguel‐Teodoro Hernández, Joan Bargay and Juan José Lahuerta and has published in prestigious journals such as New England Journal of Medicine, Blood and The Lancet Oncology.

In The Last Decade

Nuria Quintana

7 papers receiving 637 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nuria Quintana Spain	6	446	382	276	163	131	7	646
Shuhui Deng China	13	516 1.2×	475 1.2×	330 1.2×	117 0.7×	59 0.5×	83	747
Heinz-A. Horst Germany	6	443 1.0×	360 0.9×	163 0.6×	253 1.6×	87 0.7×	6	791
JP Fermand France	9	506 1.1×	283 0.7×	288 1.0×	117 0.7×	55 0.4×	16	615
D Borrego Spain	7	342 0.8×	186 0.5×	155 0.6×	105 0.6×	60 0.5×	11	414
Loredana Santo United States	9	456 1.0×	383 1.0×	326 1.2×	59 0.4×	83 0.6×	23	633
Marian Stevens‐Kroef Netherlands	14	396 0.9×	366 1.0×	153 0.6×	115 0.7×	49 0.4×	30	692
J. A. Portero Spain	8	305 0.7×	154 0.4×	128 0.5×	182 1.1×	156 1.2×	11	444
Yosra Aljawai United States	7	271 0.6×	247 0.6×	147 0.5×	217 1.3×	116 0.9×	25	567
Axelle Daviet France	9	523 1.2×	411 1.1×	185 0.7×	240 1.5×	29 0.2×	10	651
Lorenz Kleeberg Germany	10	372 0.8×	392 1.0×	359 1.3×	51 0.3×	55 0.4×	16	674

Countries citing papers authored by Nuria Quintana

Since Specialization

Citations

This map shows the geographic impact of Nuria Quintana's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nuria Quintana with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nuria Quintana more than expected).

Fields of papers citing papers by Nuria Quintana

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nuria Quintana. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nuria Quintana. The network helps show where Nuria Quintana may publish in the future.

Co-authorship network of co-authors of Nuria Quintana

This figure shows the co-authorship network connecting the top 25 collaborators of Nuria Quintana. A scholar is included among the top collaborators of Nuria Quintana based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nuria Quintana. Nuria Quintana is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Pilar Giraldo, et al.. (2016). Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. The Lancet Oncology. 17(8). 1127–1136. 107 indexed citations

Mateos, María‐Victoria, Pilar Giraldo, Javier de la Rubia, et al.. (2016). Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis. Blood. 128(22). 3308–3308. 1 indexed citations

Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Pilar Giraldo, et al.. (2014). Long Term Follow-up on the Tretament of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival. Blood. 124(21). 3465–3465. 7 indexed citations

Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Pilar Giraldo, et al.. (2013). Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine. 369(5). 438–447. 348 indexed citations

Ocio, Enrique M., Diego Fernández‐Lázaro, Laura San‐Segundo, et al.. (2011). Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM. Blood. 118(21). 134–134. 5 indexed citations

Alfonso-Pérez, Manuel, et al.. (2006). Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. Journal of Leukocyte Biology. 79(6). 1157–1165. 45 indexed citations

Quintana, Nuria, María Cabrerizo, Manuel Alfonso-Pérez, et al.. (2004). Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. Journal of Leukocyte Biology. 76(2). 462–471. 133 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact